Detalles de la búsqueda
1.
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Diabetes Obes Metab
; 23(2): 569-580, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185002
2.
Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Diabetes Obes Metab
; 21(11): 2465-2473, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297968
3.
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
JAMA
; 322(12): 1155-1166, 2019 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536101
4.
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium.
Ther Innov Regul Sci
; 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564178
5.
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold Setting.
Ther Innov Regul Sci
; 58(3): 423-430, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38321191
6.
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Diabetol Int
; 12(1): 87-100, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33479584
Resultados
1 -
6
de 6
1
Próxima >
>>